On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

Drugmakers Novo Nordisk and Eli Lilly and Company have transformed the landscape of chronic weight loss management with the ...

So far, Tecvayli has had an incremental contribution to 2025 sales of $670M; while Darzalex Faspro saw $14.4B in 2025 sales.

Health and wellness influencers are hawking unapproved treatments on the gray market. The future of the F.D.A.—and the health ...

Devonshire Cougars 4 X-Roads Warriors 2 Devonshire Cougars finished off their season by fighting back to beat X-Roads at ...

Detailed price information for Medicus Pharma Ltd (MDCX-Q) from The Globe and Mail including charting and trades.

OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...

Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

Amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is safe and ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.